IgA nephropathy: predicting the risks of progression
https://doi.org/10.17749/2070-4909/farmakoekonomika.2025.298
Abstract
Immunoglobulin A (IgA) nephropathy is the most common form of chronic glomerulonephritis and one of the leading causes of end-stage renal disease. Currently, the ability to accurately predict the risk of this progression at the individual patient level is limited. This paper analyzes the scientific literature containing research results focused on identifying independent predictors of IgA nephropathy progression risk. According to most studies, variables such as proteinuria, arterial hypertension, and baseline kidney function have a stable and independent association with worse kidney prognosis. Histological changes in kidney biopsy serve as independent predictors. The combination of morphologic and clinical data improves predictive accuracy. To enhance treatment outcomes and long-term prognosis, further research is necessary, including the search for new biomarkers and the development of a universally accepted risk stratification system.
About the Authors
D. I. Korabelnikov
Moscow Haass Medical and Social Institute
Russian Federation
Russian Federation
Daniil I. Korabelnikov, PhD, Assoc. Prof.
5 2nd Brestskaya Str., Moscow 123056
M. E. Mantsaeva
Moscow Haass Medical and Social Institute; Branch Clinical and Diagnostic Center of PJSC Gazprom; Main Clinical Hospital of the Ministry of Internal Affairs of the Russian Federation
Russian Federation
Russian Federation
Maria E. Mantsaeva
5 2nd Brestskaya Str., Moscow 123056
16 Nametkina Str., Moscow 117420
35 Narodnogo Opolcheniya Str., Moscow 123060
References
1. Shilov E.M., Smirnov A.V., Kozlovskaya N.L. (Eds) Nephrology. Clinical recommendations. Moscow: GEOTAR-Media; 2016: 816 pp. (in Russ.).
2. Bobkova I.N., Bulanov N.M., Zakharova E.V., et al. KDIGO 2021 clinical practice guideline for the management of glomerular diseases. Nephrology and Dialysis. 2022; 24 (4): 577–874 (in Russ.). https://doi.org/10.28996/2618-9801-2022-4-577-874.
3. Schena F.P., Nistor I. Epidemiology of IgA nephropathy: a global perspective. Semin Nephrol. 2018; 38 (5): 435–42. https://doi.org/10.1016/j.semnephrol.2018.05.013.
4. Soares M.F. An update on pathology of IgA nephropathy. J Bras Nefrol. 2016; 38 (4): 435–40. https://doi.org/10.5935/0101-2800.20160069.
5. Riispere Ž., Laurinavičius A., Kuudeberg A., et al. IgA nephropathy clinicopathologic study following the Oxford classification: progression peculiarities and gender-related differences. Medicina. 2016; 52 (6): 340–8. https://doi.org/10.1016/j.medici.2016.11.003.
6. Kiryluk K., Freedberg D.E., Radhakrishnan J., et al. Global incidence of IgA nephropathy by race and ethnicity: a systematic review. Kidney360. 2023; 4 (8): 1112–22. https://doi.org/10.34067/KID.0000000000000165.
7. Yamada K., Doi S., Nakashima A., et al. Expression of age-related factors during the development of renal damage in patients with IgA nephropathy. Clin Exp Nephrol. 2015; 19 (5): 830–7. https://doi.org/10.1007/s10157-014-1070-2.
8. Sato Y., Tsukaguchi H., Higasa K., et al. Positive renal familial history in IgA nephropathy is associated with worse renal outcomes: a singlecenter longitudinal study. BMC Nephrol. 2021; 22 (1): 230. https://doi.org/10.1186/s12882-021-02425-8.
9. Barbour S.J., Coppo R., Zhang H., et al. Evaluating a new international risk-prediction tool in IgA nephropathy. JAMA Intern Med. 2019; 179 (7): 942–52. https://doi.org/10.1001/jamainternmed.2019.0600.
10. Coppo R., Troyanov S., Bellur S., et al. Validation of the Oxford classification of IgA nephropathy in cohorts with different presentations and treatments. Kidney Int. 2014; 86 (4): 828–36. https://doi.org/10.1038/ki.2014.63.
11. Mohd R., Mohammad Kazmin N.E., Abdul Cader R., et al. Long term outcome of immunoglobulin A (IgA) nephropathy: a single center experience. PLoS One. 2021; 16 (4): e0249592. https://doi.org/10.1371/journal.pone.0249592.
12. Tang C., Chen P., Si F.L., et al. Time-varying proteinuria and progression of IgA nephropathy: a cohort study. Am J Kidney Dis. 2024; 84 (2): 170–8e1. https://doi.org/10.1053/j.ajkd.2023.12.016.
13. Le W., Liang S., Hu Y., et al. Long-term renal survival and related risk factors in patients with IgA nephropathy: results from a cohort of 1155 cases in a Chinese adult population. Nephrol Dial Transplant. 2012; 27 (4): 1479–85. https://doi.org/10.1093/ndt/gfr527.
14. Li X., Liu Y., Lv J., et al. Progression of IgA nephropathy under current therapy regimen in a Chinese population. Clin J Am Soc Nephrol. 2014; 9 (3): 484–9. https://doi.org/10.2215/CJN.01990213.
15. Shirai S., Yasuda T., Kumagai H., et al. Prognostic factors of IgA nephropathy presenting with mild proteinuria at the time of diagnosis (a multicenter cohort study). Clin Exp Nephrol. 2023; 27 (4): 340–8. https://doi.org/10.1007/s10157-023-02316-2.
16. Berthoux F., Mohey H., Laurent B., et al. Predicting the risk for dialysis or death in IgA nephropathy. J Am Soc Nephrol. 2011; 22 (4): 752–61. https://doi.org/10.1681/ASN.2010040355.
17. Soleymanian T., Najafi I., Salimi B.H., Broomand B. Prognostic factors and therapy assessment of IgA nephropathy: report from a single unit in Iran. Ren Fail. 2011; 33 (6): 572–7. https://doi.org/10.3109/0886022X.2011.585001.
18. Wakai K., Kawamura T., Endoh M., et al. A scoring system to predict renal outcome in IgA nephropathy: from a nationwide prospective study. Nephrol Dial Transplant. 2006; 21 (10): 2800–8. https://doi.org/10.1093/ndt/gfl342.
19. Geddes C., Rauta V., Gronhagen-Riska C., et al. A tricontinental view of IgA nephropathy. Nephrol Dial Transplant. 2003; 18 (8): 1541–8. https://doi.org/10.1093/ndt/gfg207.
20. Chen D., Liu J., Duan S., et al. Clinicopathological features to predict progression of IgA nephropathy with mild proteinuria. Kidney Blood Press Res. 2018; 43 (2): 318–28. https://doi.org/10.1159/000487901.
21. Weng M., Lin J., Chen Y., et al. Time-averaged hematuria as a prognostic indicator of renal outcome in patients with IgA nephropathy. J Clin Med. 2022; 11 (22): 6785. https://doi.org/10.3390/jcm11226785.
22. Sevillano A., Gutiérrez E., Yuste C., et al. Remission of hematuria improves renal survival in IgA nephropathy. J Am Soc Nephrol. 2017; 28 (10): 3089–99. https://doi.org/10.1681/ASN.2017010108.
23. Dobronravov V.A., Muzhetskaya T.O., Lin D.I., Kochoyan Z.Sh. Immunoglobulin A-nephropathy in Russian population: clinical and morphological presentation and long-term prognosis. Nephrology (Saint-Petersburg). 2019; 23 (6): 45–60 (in Russ.). https://doi.org/10.36485/1561-6274-2019-236-45-60.
24. Tanaka S., Ninomiya T., Katafuchi R., et al. Development and validation of a prediction rule using the Oxford classification in IgA nephropathy. Clin J Am Soc Nephrol. 2013; 8 (12): 2082–90. https://doi.org/10.2215/CJN.03480413.
25. Heybeli C., Oktan M.A, Yıldız S., et al. Clinical significance of mesangial IgM deposition in patients with IgA nephropathy. Clin Exp Nephrol. 2019; 23 (3): 371–9. https://doi.org/10.1007/s10157-0181651-6.
26. Zeng C.H., Le W., Ni Z., et al. A multicenter application and evaluation of the oxford classification of IgA nephropathy in adult chinese patients. Am J Kidney Dis. 2012; 60 (5): 812–20. https://doi.org/10.1053/j.ajkd.2012.06.011.
27. Walsh M., Sar A., Lee D., et al. Histopathologic features aid in predicting risk for progression of IgA nephropathy. Clin J Am Soc Nephrol. 2010; 5 (3): 425-30. https://doi.org/10.2215/CJN.06530909.
28. Manno C., Strippoli G.F, D'Altri C., et al. A novel simpler histological classification for renal survival in IgA nephropathy: a retrospective study. Am J Kidney Dis. 2007; 49 (6): 763–75. https://doi.org/10.1053/j.ajkd.2007.03.013.
29. Yau T., Korbet M., Schwartz M.M., et al. The Oxford classification of IgA nephropathy: a retrospective analysis. Am J Nephrol. 2011; 34 (5): 435–44. https://doi.org/10.1159/000332223.
30. Lv J., Shi S., Xu D., et al. Evaluation of the Oxford classification of IgA nephropathy: a systematic review and meta-analysis. Am J Kidney Dis. 2013; 62 (5): 891–9. https://doi.org/10.1053/j.ajkd.2013.04.021.
31. Alamartine E., Sauron С., Laurent B., et al. Use of the Oxford classification of IgA nephropathy to predict renal survival. Clin J Am Soc Nephrol. 2011; 6 (10): 2384–8. https://doi.org/10.2215/CJN.01170211.
32. Reich H.N., Troyanov S., Scholey J.W., et al. Toronto Glomerulonephritis Registry: remission of proteinuria improves prognosis in IgA nephropathy. J Am Soc Nephrol. 2007; 18 (12): 3177– 83. https://doi.org/10.1681/ASN.2007050526.
33. Bobart S.A., Alexander M.P., Shawwa K., et al. The association of microhematuria with mesangial hypercellularity, endocapillary hypercellularity, crescent score and renal outcomes in immunoglobulin A nephropathy. Nephrol Dial Transplant. 2021; 36 (5): 840–7. https://doi.org/10.1093/ndt/gfz267.
34. Schimpf J.I., Klein T., Fitzner C., et al. Renal outcomes of STOP-IgAN trial patients in relation to baseline histology (MEST-C scores). BMC Nephrol. 2018; 19 (1): 328. https://doi.org/10.1186/s12882-018-1128-6.
35. Alamartine E., Sabatier J.C., Berthoux F.C. Comparison of pathological lesions on repeated renal biopsies in 73 patients with primary IgA glomerulonephritis: value of quantitative scoring and approach to final prognosis. Clin Nephrol. 1990; 34 (2): 45–51.
36. Sakai H., Abe K., Kobayashi Y., et al. Clinical guidelines of IgA nephropathy. Nihon Jinzo Gakkai Shi. 1990; 37 (8): 417–21.
37. Lee S.M.K., Rao V.M., Franklin W.A., et al. IgA nephropathy: morphologic predictors of progressive renal disease. Hum Pathol. 1982; 13 (4): 314–22. https://doi.org/10.1016/s0046-8177(82)80221-9.
38. Thompson A., Carroll K.A., Inker L., et al. Proteinuria reduction as a surrogate end point in trials of IgA nephropathy. Clin J Am Soc Nephrol. 2019; 14 (3): 469–81. https://doi.org/10.2215/CJN.08600718.
39. Cravedi P., Remuzzi G. Pathophysiology of proteinuria and its value as an outcome measure in chronic kidney disease. Br J Clin Pharmacol. 2013; 76 (4): 516–23. https://doi.org/10.1111/bcp.12104.
40. Huang Z., Wen Q., Zhou S.F., Yu X.Q. Differential chemokine expression in tubular cells in response to urinary proteins from patients with nephrotic syndrome. Cytokine. 2008; 42 (2): 222–33. https://doi.org/10.1016/j.cyto.2008.02.005.
41. Barbour S., Reich H. An update on predicting renal progression in IgA nephropathy. Curr Opin Nephrol Hypertens. 2018; 27 (3): 214–20. https://doi.org/10.1097/MNH.0000000000000405.
42. Coppo R., D’Amico G. Factors predicting progression of IgA nephropathies. J Nephrol. 2005; 18 (5): 503–12.
43. Roberts I.S., Cook H.T., Troyanov S., et al. The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility. Kidney Int. 2009; 76 (5): 546–56. https://doi.org/10.1038/ki.2009.168.
Review
For citations:
Korabelnikov D.I., Mantsaeva M.E. IgA nephropathy: predicting the risks of progression. FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology. 2025;18(2):294–303. (In Russ.) https://doi.org/10.17749/2070-4909/farmakoekonomika.2025.298
Views:
8
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Email this article 